**FINANCES**: What resources were available to support the national program in the past six years? And what resources are available in the coming three years?

Global Fund investments:
- **2014-2016 Allocation period**
  - Tuberculosis disbursements: $25.9m
  - TB/HIV disbursements: $6.59m
  - RSSH disbursements: $4.35m

In 2015-2017, 50% of NSP need was funded.

TB financing

**Planned investments by funding source and intervention (2018-2020)**

- Total amount in budget: $59m

<table>
<thead>
<tr>
<th>Program Area</th>
<th>Label</th>
<th>Total budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>TB Care and Prevention</td>
<td>$39m</td>
</tr>
<tr>
<td>B</td>
<td>MDR-TB</td>
<td>$4m</td>
</tr>
<tr>
<td>C</td>
<td>Program Management</td>
<td>$2m</td>
</tr>
<tr>
<td>Not in graph</td>
<td>RSSH</td>
<td>$1m</td>
</tr>
<tr>
<td>Not in graph</td>
<td>TB/HIV</td>
<td>$1m</td>
</tr>
</tbody>
</table>

**OUTCOME**: How many people received the treatment and prevention services that they need?

Global Fund Results (2017)

- People with TB treated: 44.8k
- People with drug-resistant TB on treatment: 375
- HIV+ TB patients on ART: 17.1k

**IMPACT**: What is the trend among people who continue to fall ill or die? (actual and hypothetical in the absence of program)

Change in TB deaths (excluding HIV+):
- 2014-2016: 60% increase from 2012 to 2017
- 67% increase from 2000 to 2017

TB deaths (excluding HIV+)

Change in New TB cases (all forms):
- 16% increase from 2012 to 2017
- 29% increase from 2000 to 2017

Notes: Detailed notes are available on the separate Explanatory Notes page.